[go: up one dir, main page]

WO2011117322A3 - Use of caffeine and aspirin in synergistic amounts for improving performance - Google Patents

Use of caffeine and aspirin in synergistic amounts for improving performance Download PDF

Info

Publication number
WO2011117322A3
WO2011117322A3 PCT/EP2011/054496 EP2011054496W WO2011117322A3 WO 2011117322 A3 WO2011117322 A3 WO 2011117322A3 EP 2011054496 W EP2011054496 W EP 2011054496W WO 2011117322 A3 WO2011117322 A3 WO 2011117322A3
Authority
WO
WIPO (PCT)
Prior art keywords
caffeine
aspirin
enhanced
produce
ergogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/054496
Other languages
French (fr)
Other versions
WO2011117322A2 (en
Inventor
John Paul Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011117322A2 publication Critical patent/WO2011117322A2/en
Publication of WO2011117322A3 publication Critical patent/WO2011117322A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides use of caffeine and aspirin, the aspirin being used in an amount effective to produce an enhanced ergogenic effect of the caffeine when ingested by a person desiring enhanced performance in sporting activity or desiring enhanced cognitive performance. The present invention also provides a composition comprising caffeine and aspirin, the aspirin being included in the composition in an amount effective to produce an enhanced ergogenic effect of the caffeine when ingested by a person desiring enhanced cognitive or physical performance, e.g. in sporting activity. Thus, the present invention provides an ergogenic composition for producing enhanced cognitive performance as well as enhanced physical performance e.g. in sporting activity, the caffeine being included in an amount to produce an ergogenic effect in humans; and the aspirin being included in an amount effective to produce a synergistic effect with caffeine thereby resulting in an enhanced ergogenic effect of caffeine.
PCT/EP2011/054496 2010-03-23 2011-03-23 Use of caffeine and aspirin in synergistic amounts for improving performance Ceased WO2011117322A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1004831.2A GB2478931B (en) 2010-03-23 2010-03-23 Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity
GB1004831.2 2010-03-23

Publications (2)

Publication Number Publication Date
WO2011117322A2 WO2011117322A2 (en) 2011-09-29
WO2011117322A3 true WO2011117322A3 (en) 2012-01-12

Family

ID=42228176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/054496 Ceased WO2011117322A2 (en) 2010-03-23 2011-03-23 Use of caffeine and aspirin in synergistic amounts for improving performance

Country Status (2)

Country Link
GB (1) GB2478931B (en)
WO (1) WO2011117322A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003681A1 (en) * 1984-12-26 1986-07-03 Abraham Sunshine Analgesic, anti-inflammatory and skeletal muscle relaxant compositions
US5055460A (en) * 1990-04-26 1991-10-08 Mitchell Friedlander Method for weight loss
WO1999003475A1 (en) * 1997-07-14 1999-01-28 Bristol-Myers Squibb Company Use of compositions containing the combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1137379A (en) * 1912-12-21 1915-04-27 Alfred W Beuttell Show-case light.
AU784112B2 (en) * 1999-04-06 2006-02-09 Wm. Wrigley Jr. Company Pharmaceutical chewing gum formulations
US20060292225A1 (en) * 2005-06-24 2006-12-28 Felix Arthur M Water soluble analgesic formulations and methods for production
WO2007056176A2 (en) * 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003681A1 (en) * 1984-12-26 1986-07-03 Abraham Sunshine Analgesic, anti-inflammatory and skeletal muscle relaxant compositions
US5055460A (en) * 1990-04-26 1991-10-08 Mitchell Friedlander Method for weight loss
WO1999003475A1 (en) * 1997-07-14 1999-01-28 Bristol-Myers Squibb Company Use of compositions containing the combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.J. MEDINA: "How does Ripped Fuel work?", 12 September 2009 (2009-09-12), XP002660406, Retrieved from the Internet <URL:http://www.livestrong.com/article/32157-ripped-fuel-work/> [retrieved on 20110930] *
FERNANDEZ-DUENAS ET AL: "Adjuvant effect of caffeine on acetylsalicylic acid anti-nociception: Prostaglandin E2 synthesis determination in carrageenan-induced peripheral inflammation in rat", EUROPEAN JOURNAL OF PAIN, SAUNDERS, LONDON, GB, vol. 12, no. 2, 30 November 2007 (2007-11-30), pages 157 - 163, XP022367496, ISSN: 1090-3801, DOI: 10.1016/J.EJPAIN.2007.03.485 *
GRAHAM T E: "Caffeine and exercise: metabolism, endurance and performance", SPORTS MEDICINE, ADIS PRESS, AUCKLAND, NZ, vol. 31, no. 11, 1 January 2001 (2001-01-01), pages 785 - 807, XP008084424, ISSN: 0112-1642, DOI: 10.2165/00007256-200131110-00002 *
HUDSON GEOFFREY M ET AL: "Effects of caffeine and aspirin on light resistance training performance, perceived exertion, and pain perception", JOURNAL OF STRENGTH AND CONDITIONING RESEARCH, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 22, no. 6, 1 November 2008 (2008-11-01), pages 1950 - 1957, XP008143297, ISSN: 1064-8011, DOI: 10.1519/JSC.0B013E31818219CB *
JAMES COLLIER: "Ephedrine & Ephedra, and the Associated Alkaloids and Compounds :: Part 2", 1 November 2009 (2009-11-01), XP002660405, Retrieved from the Internet <URL:http://articles.muscletalk.co.uk/article-ephedrine-ephedra-2.aspx> [retrieved on 20110927] *
RUBIN A ET AL: "A double-blind randomized study of an aspirin/caffeine combination versus acetaminophen/aspirin combination versus acetaminophen versus placebo in patients with moderate to severe post-partum pain.", THE JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 1984 LNKD- PUBMED:6519349, vol. 12, no. 6, 1984, pages 338 - 345, XP008143653, ISSN: 0300-0605 *
UTAH POISON CONTROL CENTER: "Drug Abuse in Sports", UTOX UPDATE, 1 January 2002 (2002-01-01), pages 1 - 4, XP055008570, Retrieved from the Internet <URL:http://uuhsc.utah.edu/poison/healthpros/utox/vol4_no1.pdf> [retrieved on 20110930] *

Also Published As

Publication number Publication date
WO2011117322A2 (en) 2011-09-29
GB2478931B (en) 2013-06-12
GB2478931A (en) 2011-09-28
GB201004831D0 (en) 2010-05-05

Similar Documents

Publication Publication Date Title
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
WO2011107462A3 (en) Sun protection compositions
CR20110485A (en) 2-ACETAMIDO-5-ARIL-1,2,4-SUBSTITUTED TRIAZOLONES AND ITS USE
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
WO2015010009A3 (en) Compositions and methods comprising a lipolytic enzyme variant
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
WO2009089494A3 (en) Pharmaceutical compositions
IT1402907B1 (en) TOPIC COMPOSITIONS TO MAINTAIN OR RESTORE THE INTEGRITY OF THE MUCOSE.
WO2013175221A3 (en) Composition
LT2739615T (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
WO2013034855A3 (en) Combination of carrageenan and c-glycoside and uses thereof
JP2014500291A5 (en)
WO2012093973A3 (en) Compositions in the form of tablets comprising acarbose
WO2014124398A3 (en) Assemblies for personal restraint
WO2012173382A3 (en) Skin composition for external use containing tanshinone ii a as active ingredient
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
WO2012065028A3 (en) Substituted tetracyclines
GB201020119D0 (en) Pharamaceutical and other compositions, e.g. for the skin, comprising emulsifying ointment and water
WO2011117322A3 (en) Use of caffeine and aspirin in synergistic amounts for improving performance
NZ613887A (en) Antimicrobial activity enhancing agent
WO2011018477A3 (en) Carnosol for hair and skin care
WO2013012309A8 (en) External preparation for skin
曾勇 Journal of UESTC (Social Sciences Edition) Jun. 2009, Vol. 11, No. 3
TH114110S (en) seat
TH118830S (en) Safety accessories for locking devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11714714

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11714714

Country of ref document: EP

Kind code of ref document: A2